08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

APPY1 regulatory update

Venaxis said FDA issued a not substantially equivalent response to the company’s 501(k) application for APPY1 to aid emergency room clinicians in identifying patients at low risk for appendicitis in individuals ages 2-20 with abdominal...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Clinical News

APPY1 regulatory update

Venaxis submitted a response to FDA’s request for information related to its 510(k) application for APPY1 to aid emergency room clinicians in identifying patients at low risk for appendicitis in individuals ages 2-20 years with...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Financial News

Venaxis financial update

Venaxis Inc. (NASDAQ:APPY), Castle Rock, Colo.   Business: Diagnostic   Date announced: 2014-12-17   Note: Venaxis filed a shelf registration covering the sale of up to $50 million of its common stock. The company, which...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Financial News

BiOptix completes venture financing

BiOptix Diagnostics Inc. , Boulder, Colo.   Business: Diagnostic   Date completed: 2014-08-13   Type: Venture financing   Raised: $1.4 million   Investor: Existing investors  ...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

APPY1 regulatory update

Venaxis said FDA provided the company with questions and requested information as part of the agency’s review of a 510(k) application for APPY1 to identify patients that are at low risk for appendicitis. The company...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

3Q14 Financial Markets Preview: Discerning optimism

Investors and bankers are cautiously optimistic that the correction that began in late 1Q14 will provide a floor for a biotech recovery that should continue through the third quarter, with investors being more selective on...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Clinical News

APPY1 regulatory update

Venaxis submitted a 510(k) application to FDA for APPY1 to identify patients that are at low risk for appendicitis. The company is also seeking concurrent de novo classification of the test by FDA. FDA's de...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Financial News

Venaxis completes follow-on

Venaxis Inc. (NASDAQ:APPY), Castle Rock, Colo.   Business: Diagnostic   Date completed: 4/3/14   Type: Follow-on   Raised: $20 million   Shares: 8.3 million   Price: $2.40   Shares after offering: 30.6 million   Underwriters:...
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was off $1.66 to $68.44 last week after FDA's Anti-Infective Drugs Advisory Committee voted unanimously in favor of approval of Sivextro tedizolid to treat acute bacterial skin and skin...
00:34 , Apr 4, 2014 |  BC Extra  |  Financial News

Venaxis raises $20 million in follow-on

Venaxis Inc. (NASDAQ:APPY) raised $20 million through the sale of 8.3 million shares at $2.40 in a follow-on underwritten by Canaccord and Craig-Hallum Capital. Venaxis proposed the offering late Wednesday, when its share price was...